Drugs / REGN7544
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05970718 | Aug 2023 → Jul 2024 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06608901 | May 2025 → Feb 2026 | infectious disease with sepsis | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT06593600 | Nov 2024 → May 2026 overdue | postural orthostatic tachycardia syndrome | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7544 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05970718 ↗ |
| Action | Inhibit | “Antagonistic Monoclonal Antibody to NPR1” NCT05970718 ↗ |
| Modality | Monoclonal antibody | “an Antagonistic Monoclonal Antibody to NPR1” NCT05970718 ↗ |
| Route | Intravenous | “single ascending Intravenous (IV) or Subcutaneous (SC) administration” NCT05970718 ↗ |
| Route | Subcutaneous | “single ascending Intravenous (IV) or Subcutaneous (SC) administration” NCT05970718 ↗ |
| Target | NPR1 | “an Antagonistic Monoclonal Antibody to NPR1” NCT05970718 ↗ |